RxDoctor Payments Data

Pranjalkumar Patel, MD

Family Medicine · Tracy, CANPI 1225233133

Payments from drug & device makers

$18,174in general payments, 2019–2025

Across 996 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Sanofi-aventis U.S. LLC$995
  • GSK$994
  • Boehringer Ingelheim$895
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$18,08299%
  • Education$921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)98$2,896
Novo Nordisk183$2,389
Lilly USA, LLC56$1,137
Sanofi-aventis U.S. LLC63$995
GSK76$994
Boehringer Ingelheim40$895
Merck48$781
Kowa Pharmaceuticals America, Inc.43$687
Pfizer34$612
Amgen(2 entities)25$605
Bayer18$588
Johnson & Johnson23$588
Esperion Therapeutics, Inc.30$474
AbbVie(2 entities)33$467
Sumitomo Pharma America, Inc.25$397
Otsuka America Pharmaceutical, Inc.16$311
Vanda Pharmaceuticals Inc.14$306
Novartis18$275
Amarin Pharma, Inc.11$269
Astellas Pharma US Inc10$244
Abbott11$184
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$158
UCB, Inc.6$144
Sunovion Pharmaceuticals Inc.9$135
Xeris Pharmaceuticals, Inc.6$100
Biohaven Pharmaceutical Holding Company Ltd.5$94
Lundbeck LLC6$90
Avanir Pharmaceuticals, Inc.6$89
Eisai Inc.4$83
Acadia Pharmaceuticals Inc5$74
Corcept Therapeutics4$74
Akebia Therapeutics Inc5$72
Teva Pharmaceuticals USA, Inc.5$68
Mylan Specialty L.p.4$67
E.r. Squibb & Sons, L.L.C.3$57
Indivior Inc.3$56
Axsome Therapeutics, Inc.2$53
Redhill Biopharma Inc.3$46
Exact Sciences2$42
Sanofi Pasteur Inc.2$42
Dexcom, Inc.2$42
Biohaven Pharmaceuticals, Inc.2$37
Lifescan, Inc.2$36
Genentech USA, Inc.2$36
Mannkind Corporation2$31
Vifor Pharma, Inc.2$28
Sanofi1$26
Radius Health, Inc.1$23
Argenx US, Inc.1$22
Arbor Pharmaceuticals, Inc.1$20
Scilex Pharmaceuticals Inc.1$20
Alfasigma USA, Inc.1$20
Phathom Pharmaceuticals, Inc.1$20
Qiagen, LLC1$19
Takeda Pharmaceuticals U.S.A., Inc.1$18
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$18
Nevro Corp.1$17
Insulet Corporation1$17
Biogen1$15
Neurocrine Biosciences, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,174 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$964,195
Medicare patients
990
Services billed
12,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide410$541,275
EliquisApixaban516$328,399
FarxigaDapagliflozin Propanediol253$276,721
JardianceEmpagliflozin207$221,190
ProliaDenosumab82$140,661
Trelegy ElliptaFluticasone/Umeclidin/Vilanter205$140,584
RybelsusSemaglutide46$76,048
LinzessLinaclotide91$73,420
JanuviaSitagliptin Phosphate79$70,012
TrulicityDulaglutide41$67,536
Breo ElliptaFluticasone/Vilanterol144$64,536
XareltoRivaroxaban47$58,687
MounjaroTirzepatide43$56,098
MyrbetriqMirabegron69$53,940
TradjentaLinagliptin108$49,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,389$617,323456 claims
PfizerEliquis$612$328,399516 claims
AstraZenecaFarxiga, Breztri Aerosphere$2,896$299,115280 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$895$290,668340 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$994$214,066369 claims
AmgenProlia$605$140,66182 claims
Lilly USA, LLCTrulicity, Mounjaro$1,137$123,63584 claims
AbbVieLinzess$467$73,42091 claims
Johnson & JohnsonXarelto, Procrit$588$71,66562 claims
MerckJanuvia$781$70,01279 claims
Astellas Pharma US IncMyrbetriq$244$53,94069 claims
Sanofi-aventis U.S. LLCMultaq$995$17,72219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Tracy

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →